Neurotechnology Following Traumatic Brain Injury

Inclusion Criteria: * 1 Must have symptoms related to concussion or TBI, not healthy controls Age 18 years or older. * 2 Active duty or retired military service member, or dependent beneficiary. * 3 History of mild TBI, confirmed by administration of the Ohio State University TBI * Identification Method Interview. * 4 At least three months, and no more than ten years, since their most recent TBI. * 5 Persistent symptoms temporally related, or otherwise attributable to, the TBI, such as * headache or chronic pain, sensory disturbance including auditory, visual or other sensory * symptoms, balance difficulties, or dizziness. After obtaining informed consent, sufficient * severity of symptoms for entry into the study will be confirmed by administration of the * Neurobehavioral Symptom Inventory (NSI), with a score of 23 or higher required for * inclusion. * 6 Willingness to be randomly assigned to one of the two treatment groups and to provide * data for all study measures. * 7 Willingness to abstain from alcohol or recreational drug use throughout the intervention * period and up to 3 weeks after completion of the final office-based intervention session. * This abstention period is intended to support the stabilization of new brain activity * patterns that may result from the intervention. * 8 For individuals using any of the following medication classes (either regularly scheduled * or PRN), a willingness both to discontinue or hold those medications at least five (5) halflives * prior to the initiation of study procedures, and throughout the period of participation * in the study, as well as to sign a release enabling contact between study staff and their * prescribing provider, to ensure that the prescriber deems that holding said medication * during the study period is permissible and reasonable: benzodiazepines, opioids, antipsychotics, * mood-stabilizers, anti-convulsants, non-benzodiazepine sleep aids (including * but not limited zolpidem, eszoplicone, zaleplon, trazadone, and diphenhydramine), other * prescribed sedative-hypnotics, or medical marijuana or cannabinoid medication. * 9 Willingness to abstain from initiation of PRN/as needed usage of the above listed * medications throughout the period of study participation. This criterion only applies to * new PRN prescription or usage. There is no requirement to abstain from a new, regularly scheduled prescription for one of the above medications during the course of the study, if the participant's provider * deems such usage to be indicated. The potential impact of the initiation of any such * medications during the study will be assessed by conducting sensitivity analyses after the * completion of the study. * 10 Willingness to alert study investigators of any changes in their medication usage * throughout the course of their study participation. Exclusion Criteria: * 1 Unable or unwilling to demonstrate an understanding of the nature and intent of the * study, and/or to complete informed consent procedures. * 2 A history of moderate or severe TBI. * 3 The diagnosis of a psychotic disorder (including schizophrenia and schizoaffective * disorder), severe depression (PHQ-9 score \> 20), bipolar disorder, or active suicidal or * homicidal ideation. * 4 Physically unable to come to the study visits, or to sit in a chair for up to two hours. * 5 Inability to hear and repeat a phrase spoken at normal conversational volume. * 6 Meeting criteria for a current alcohol or substance use disorder.